Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Therapy Directory

Sotorasib clinical trials

Directory of U.S. ClinicalTrials.gov public records that list Sotorasib as a study intervention. Browse Sotorasib recruiting trials, filter by phase, sponsor, or location, and open the official ClinicalTrials.gov study record for each result.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 9:48 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
52
Shown on this page
12
Current sort
Recently updated
Therapy scope
Sotorasib
Additional filters apply within this therapy.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this therapy

These controls apply only within Sotorasib. Default order is Recently updated. Add condition, location, sponsor, or recruitment status to narrow this therapy page further.

Reset therapy filters
Clear filters
Showing 13–24 of 52 matching trials for Sotorasib.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Open in full search
Completed Phase 3 Interventional Results available

Sotorasib and Panitumumab Versus Investigator's Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation

NCT05198934
View directory record Official record
Conditions
Colorectal Cancer (CRC)
Interventions
Sotorasib, Panitumumab, Trifluridine and Tipiracil, Regorafenib
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 100 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
20
States / cities
Birmingham, Alabama • Duarte, California • Orange, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 17, 2026, 9:48 PM EDT
Completed Phase 3 Interventional Results available

Study to Compare AMG 510 "Proposed INN Sotorasib" With Docetaxel in Non Small Cell Lung Cancer (NSCLC) (CodeBreak 200).

NCT04303780
View directory record Official record
Conditions
KRAS p, G12c Mutated /Advanced Metastatic NSCLC
Interventions
AMG 510, Docetaxel
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 100 Years
Enrollment
345 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
54
States / cities
Anaheim, California • Duarte, California • Long Beach, California + 46 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 17, 2026, 9:48 PM EDT
Terminated Phase 2 Interventional Results available

A Study of Sotorasib (AMG 510) in Participants With Stage IV NSCLC Whose Tumors Harbor a KRAS p.G12C Mutation in Need of First-line Treatment

NCT04933695
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Sotorasib
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
30
States / cities
Birmingham, Alabama • Tucson, Arizona • Duarte, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 17, 2026, 9:48 PM EDT
Active, not recruiting Phase 2 Interventional

A Phase II Study of Neoadjuvant Sotorasib in Combination With Cisplatin or Carboplatin and Pemetrexed for Surgically Resectable Stage IIA-IIIB Non-Squamous Non-Small Cell Lung Cancer With a KRAS p.G12C Mutation

NCT05118854
View directory record Official record
Conditions
Lung Cancer
Interventions
AMG 510, Cisplatin, Carboplatin, Pemetrexed
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
2
States / cities
New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 17, 2026, 9:48 PM EDT
Completed Phase 1Phase 2 Interventional

A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100)

NCT03600883
View directory record Official record
Conditions
KRAS p.G12C Mutant Advanced Solid Tumors
Interventions
sotorasib, Anti PD-1/L1, Midazolam
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 100 Years
Enrollment
713 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
39
States / cities
Duarte, California • Los Angeles, California • San Francisco, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 17, 2026, 9:48 PM EDT
Active, not recruiting Phase 1 Interventional

Anvumetostat Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104).

NCT06333951
View directory record Official record
Conditions
Thoracic Tumors, Non-small Cell Lung Cancer
Interventions
Anvumetostat, Carboplatin, Paclitaxel, Pembrolizumab, Pemetrexed, Sotorasib
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 100 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
26
States / cities
Bakersfield, California • Duarte, California • Los Angeles, California + 20 more
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Oct 17, 2026, 9:48 PM EDT
Recruiting Phase 1 Interventional

A Study of Sotorasib in People With Brain Tumors

NCT06807619
View directory record Official record
Conditions
Brain Tumor
Interventions
Sotorasib
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Commack, New York + 3 more
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 17, 2026, 9:48 PM EDT
Recruiting Phase 1Phase 2 Interventional

A 2-part Phase 1/2 Open-label Trial on ODM-212

NCT07563738
View directory record Official record
Conditions
Mesothelioma, Pancreatic Cancer, NSCLC (Advanced Non-small Cell Lung Cancer)
Interventions
ODM-212, Ipilimumab and nivolumab, Gemcitabine and nab-paclitaxel, sotorasib
Drug
Lead sponsor
Orion Corporation, Orion Pharma
Industry
Eligibility
18 Years and older
Enrollment
229 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
2
States / cities
Irving, Texas • Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Oct 17, 2026, 9:48 PM EDT
Terminated Phase 1 Interventional

A Study of NB004 as Monotherapy or Combination Therapy in Patients With Advanced Solid Tumors

NCT05036291
View directory record Official record
Conditions
Advanced Solid Tumor
Interventions
NB004 tablets
Drug
Lead sponsor
Ningbo Newbay Technology Development Co., Ltd
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
2
States / cities
New Orleans, Louisiana • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Oct 17, 2026, 9:48 PM EDT
Terminated Phase 1 Interventional

Study of Inlexisertib (DCC-3116) in Participants With RAS/MAPK Pathway Mutant Solid Tumors

NCT04892017
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, Advanced Solid Tumor, Metastatic Solid Tumor
Interventions
Inlexisertib, Trametinib, Binimetinib, Sotorasib
Drug
Lead sponsor
Deciphera Pharmaceuticals, LLC
Industry
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
10
States / cities
Boston, Massachusetts • St Louis, Missouri • New Brunswick, New Jersey + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Oct 17, 2026, 9:48 PM EDT
Recruiting Phase 1 Interventional

Carfilzomib in Combination With Sotorasib for the Treatment of Patients With KRAS G12C Mutated Advanced or Metastatic Non-small Cell Lung Cancer

NCT06249282
View directory record Official record
Conditions
Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
Interventions
Biopsy, Biospecimen Collection, Carfilzomib, Computed Tomography, Echocardiography, Magnetic Resonance Imaging, Sotorasib
Procedure · Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
2
States / cities
Duarte, California • Irvine, California
Source: ClinicalTrials.gov public record
Updated Apr 3, 2026 · Synced Oct 17, 2026, 9:48 PM EDT
Recruiting Phase 1 Interventional

A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-159642 in Participants With Advanced Solid Tumors

NCT06804824
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
VVD-159642, Sotorasib, Trametinib
Drug
Lead sponsor
Vividion Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
7
States / cities
Grand Rapids, Michigan • Austin, Texas • Irving, Texas + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Oct 17, 2026, 9:48 PM EDT

About this Sotorasib clinical trials directory page

What this page lists
U.S. ClinicalTrials.gov public records that list Sotorasib as a study intervention, including recruiting, not yet recruiting, and active not recruiting trials.
How to narrow results
Use the filters above to scope by condition, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Sotorasib.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Related: all therapy pages, browse by condition, browse by U.S. city, browse by sponsor, or open the full search for Sotorasib.